iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 …

Published December 12, 2010

iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US …
VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 8, 2010) – iCo Therapeutics Inc. (TSX VENTURE:ICO) (the “Company”) today announced that iCo has granted Immune Pharmaceuticals (IMPH), based in Israel and the United States, an option to an exclusive license for the development and commercialization rights to the systemic uses of iCo-008, iCo’s human monoclonal antibody targeting eotaxin-1.
Read more on Marketwire

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction
VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of …
Read more on News-Medical-Net

Education notes: Dec. 8
Awards/honors■ Russell Carpenter, director of Eastern Kentucky
Read more on Lexington Herald-Leader